Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)

Clinical Trial ID NCT02210117

PubWeight™ 18.10^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02210117

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Molecular and cellular insights into T cell exhaustion.	Nat Rev Immunol	2015	2.74
2	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
3	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.	Proc Natl Acad Sci U S A	2015	1.54
4	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2015	1.06
5	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.	J Clin Invest	2015	0.98
6	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.	Front Oncol	2015	0.92
7	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.	Nat Rev Urol	2016	0.84
8	Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.	Biomed Res Int	2015	0.83
9	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.	Semin Oncol	2015	0.82
10	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.	Ther Adv Med Oncol	2016	0.81
11	Therapeutic challenges in renal cell carcinoma.	Am J Clin Exp Urol	2015	0.80
12	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.	Oncotarget	2015	0.79
13	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.	Urol Oncol	2015	0.78
14	Challenges and future perspectives of T cell immunotherapy in cancer.	Immunol Lett	2015	0.78
15	An update on current management of advanced renal cell cancer, biomarkers, and future directions.	Ann Cancer Res	2015	0.76
16	Medical treatment of renal cancer: new horizons.	Br J Cancer	2016	0.76
17	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.	J Immunother Cancer	2016	0.75
18	Immunotherapy in genitourinary malignancies.	Curr Opin Urol	2016	0.75
19	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.	J Immunother Cancer	2016	0.75